Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.42 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.42 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1501849 | 0.86 | CYP11B1 (0.50) | CYP11B1CYP11B2IDO1MAOBHPGDS | |
| SCHEMBL1502376 | 0.85 | CYP11B1 (0.46) | CYP11B1CYP11B2IDO1HPGDSSLC16A3 | |
| SCHEMBL1501897 | 0.84 | CYP11B1 (0.48) | CYP11B1CYP11B2IDO1MAOBHPGDS | |
| SCHEMBL29365776 | 0.84 | MAOB (0.48) | MAOBHRH3BCHEPDE4BMAPK1 | |
| SCHEMBL1502227 | 0.83 | CYP11B1 (0.47) | CYP11B1CYP11B2IDO1MAOBHPGDS | |
| SCHEMBL1502297 | 0.82 | CYP11B1 (0.46) | CYP11B1CYP11B2IDO1MAOBHPGDS | |
| SCHEMBL1501829 | 0.82 | CYP11B1 (0.38) | CYP11B1CYP11B2IDO1HPGDS | |
| SCHEMBL1502215 | 0.81 | HPGDS (0.54) | IDO1MAOBHPGDSBCHEMAPK1 | |
| SCHEMBL13531373 | 0.81 | NPC1 (0.44) | CYP11B1CYP11B2IDO1HPGDS | |
| SCHEMBL1948994 | 0.80 | CYP11B1 (0.60) | CYP11B1CYP11B2IDO1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CYP11B1 1122/4885CYP11B2 1149/4885IDO1 1/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | CYP11B1 1122/4885CYP11B2 1149/4885IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.